Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.45−0.16 (-26.87%)
Close on Nov 16, 2026Market cap $259.49KP/E –Yield –
Virax Biolabs cash
Cash and short-term investments held at the end of each period.
Virax Biolabs's cash was $6.44M at Mar 31, 2026. For fiscal 2026 it was $6.44M, up 52.3% from the year before. The highest annual figure on record is $9.35M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $6.44M | +52.3% |
| FY2025 | Mar 31, 2025 | $4.23M | +17.8% |
| FY2024 | Mar 31, 2024 | $3.59M | -61.6% |
| FY2023 | Mar 31, 2023 | $9.35M | +42888.3% |
| FY2022 | Mar 31, 2022 | $21.76K | +23.5% |
| FY2021 | Mar 31, 2021 | $17.62K | -22.1% |
| FY2020 | Apr 1, 2020 | $22.61K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $6.44M | +29496.0% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $4.23M | +23899.5% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $3.59M | +15775.3% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $9.35M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $21.76K | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $17.62K | – |
| Q4 FY2020CQ1 2020 | Apr 1, 2020 | $22.61K | – |
See a number that looks wrong?